ganirelix
(OVBICQMTCPFEBS-SATRDZAXSA-N)
Structure
- SMILES
- CC(=O)O.CC(=O)O.CCNC(=NCCCC[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)C)CCCCN=C(NCC)NCC)CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)C)Cc1ccc(cc1)Cl)Cc1cccnc1)CO)Cc1ccc(cc1)O)NCC
- Molecular Formula:
- C84H121ClN18O17
- Molecular Weight:
- 1690.420
- Log P:
- 8.1744
- Hydrogen Bond Acceptor:
- 35
- Hydrogen Bond Donor:
- 18
- TPSA:
- 526.09
- CAS Number(s):
- 129311-55-3
Synonym(s)
1.
ganirelix
2.
Antagon
3.
GnRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)-
4.
LHRH, N-acetyl-2-naphthylalanyl(1)-(4-chlorophenylalanyl)(2)-3-pyrdinylalanyl(3)-diethylhomoarginyl(6,8)-alaninamide(10)-
5.
LHRH,N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)-
6.
N-Ac-(2-naphthyl)Ala-2-(4-Cl-Phe)-3-(3-pyridinyl-Ala)-6,8-Et2-hArg-10-AlaNH2-LHRH
7.
N-acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N(sup 6)-(N,N'-diethylamidino)-D-lysyl-L-leucyl-N(sup 6)-(N,N'-diethylamidino)-L-lysyl-L-prolyl-D-alaninamide diacetate (salt)
8.
RS 26306
9.
RS-26306
10.
RS-26306-298
11.
ganirelix acetate
12.
ganirelix diacetate
13.
orgalutran
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | No adverse event | FAERS: 7 | US FAERS | |
| 2 | Product quality issue | FAERS: 5 | US FAERS | |
| 3 | Injection site pruritus | FAERS: 3 | US FAERS | |
| 4 | Injection site urticaria | FAERS: 3 | US FAERS | |
| 5 | Maternal exposure during pregnancy | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 6 | Incorrect storage of drug | FAERS: 2 | US FAERS | |
| 7 | Injection site erythema | FAERS: 2 | US FAERS | |
| 8 | Injury associated with device | FAERS: 2 | US FAERS | |
| 9 | Low birth weight baby | FAERS: 2 | US FAERS | |
| 10 | Needle issue | FAERS: 2 | US FAERS | |
| 11 | Neonatal pneumonia | FAERS: 2 | US FAERS | |
| 12 | Accidental exposure to product | FAERS: 1 | US FAERS | |
| 13 | Air Embolism | FAERS: 1 | US FAERS | |
| 14 | Amnesia | FAERS: 1 | US FAERS | |
| 15 | Arthralgia | FAERS: 1 | US FAERS | |
| 16 | Arthritis | FAERS: 1 | US FAERS | |
| 17 | Burning sensation | FAERS: 1 | US FAERS | |
| 18 | Documented hypersensitivity to administered drug | FAERS: 1 | US FAERS | |
| 19 | Erythema | FAERS: 1 | US FAERS | |
| 20 | Flushing | FAERS: 1 | US FAERS | |
| 21 | HELLP Syndrome | FAERS: 1 | US FAERS | |
| 22 | Headache | FAERS: 1 | US FAERS | |
| 23 | Inappropriate schedule of drug administration | FAERS: 1 | US FAERS | |
| 24 | Incorrect dose administered | FAERS: 1 | US FAERS | |
| 25 | Incorrect product storage | FAERS: 1 | US FAERS | |
| 26 | Injection Site Reaction | FAERS: 1 | US FAERS | |
| 27 | Injection site pain | FAERS: 1 | US FAERS | |
| 28 | Injection site warmth | FAERS: 1 | US FAERS | |
| 29 | Ovarian Hyperstimulation Syndrome | FAERS: 1 | US FAERS | |
| 30 | Peripheral swelling | FAERS: 1 | US FAERS | |
| 31 | Pregnancy | FAERS: 1 | US FAERS | |
| 32 | Premature ovulation | FAERS: 1 | US FAERS | |
| 33 | Pruritus | FAERS: 1 | US FAERS | |
| 34 | Skin irritation | FAERS: 1 | US FAERS | |
| 35 | Syringe issue | FAERS: 1 | US FAERS | |
| 36 | Urinary Incontinence | FAERS: 1 | US FAERS | |
| 37 | Decreased embryo viability | Canada Vigilance: 1 | Canada Vigilance | |
| 38 | Drug exposure before pregnancy | Canada Vigilance: 1 | Canada Vigilance | |
| 39 | Drug ineffective | Canada Vigilance: 2 | Canada Vigilance | |
| 40 | Maternal exposure before pregnancy | Canada Vigilance: 1 | Canada Vigilance | |
| 41 | Therapy non-responder | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.